An update on the pharmacological treatment of obsessive-compulsive disorder

  title={An update on the pharmacological treatment of obsessive-compulsive disorder},
  author={Leonardo Franklin Fontenelle and Antonio Leandro Nascimento and Mauro Vitor Mendlowicz and Roseli Gedanke Shavitt and M{\'a}rcio Versiani},
  journal={Expert Opinion on Pharmacotherapy},
  pages={563 - 583}
The purpose of this article is to introduce the reader to an updated evidence-based drug treatment algorithm to be employed in patients with obsessive-compulsive disorder (OCD). Relevant studies were identified through a comprehensive review and classified according to the type of patients enrolled, the quality of the study design and the invasiveness, availability and complexity of the therapeutic approach. When ineffective, therapeutic trials with first-line strategies (such as the selective… 

Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report

  • Ö. Uzun
  • Psychology, Medicine
    Journal of psychopharmacology
  • 2010
Some preliminary evidence that the addition of glutamatergic agent lamotrigine may be useful in treatment-resistant OCD is suggested, however, further controlled studies are needed to support this finding.

[Resistance and refractoriness in obsessive-compulsive disorder].

The literature evinces that intrinsic and/or extrinsic phenomenological aspects of obsessive-compulsive disorder may collaborate to the fact that, at least 30% of obsessive, compulsive disorder patients do not respond to conventional treatment.


Obsessive-compulsive disorder (OCD) is a relatively common disorder, most of the time under diagnosed and under treated despite the existence of effective treatments. OCD can be discriminated from

Management of obsessive-compulsive disorder with fluvoxamine extended release

Its pharmacokinetic profile and its pattern of side effects may hinder a rapid dose escalation, a therapeutic strategy that might be utterly desirable in patients with obsessive-compulsive disorder (OCD).

Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study

This study of mavoglurant in OCD was terminated because of the lack of efficacy at interim analysis, and the study did not support the use of an antagonist of mGluR5 receptors for OCD treatment.

Electroconvulsive therapy in obsessive-compulsive disorder: a chart review and evaluation of its potential therapeutic effects.

In a chart review of patients with obsessive-compulsive disorder (OCD) attending a university clinic, ECT was prescribed for five subjects (1.2%), only because of severe intervening manic (N=1) or

Obsessive-Compulsive Disorder, Impulse Control Disorders and Drug Addiction

The treatment of patients with these disorders must account for alterations in the underlying motivations and neurobiology of the condition, and an initial guide to the specific treatments that future clinical trials might consider in patients with OCD is provided.

Resistance and refractoriness in obsessive- compulsive disorder Resistência e refratariedade no transtorno obsessivo-compulsivo

The literature demonstrates that intrinsic and/or extrinsic phenomenological aspects of obsessive-compulsive disorder may collaborate to the fact that, at least 30% of obsessive, compulsive disorder patients do not respond to conventional treatment.

Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive–Compulsive Disorder in Childhood

Aripiprazole augmentation of SSRIs is a promising strategy in the management of treatment-refractory OCD children and adolescents.

Anterior capsulotomy for obsessive-compulsive disorder: a review of old and new literature.

AC is a safe, well-tolerated, and efficacious therapy, and its underuse is likely a result of historical prejudice rather than lack of clinical effectiveness.



A review of pharmacologic treatments for obsessive-compulsive disorder.

Obsessive-compulsive disorder is a chronic and often disabling disorder that affects 2 to 3 percent of the U.S. population, and agents that alter serotonin receptors and other neurotransmitter systems, such as dopamine, norepinephrine, and second-messenger systems, may play a role in treatment.

Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder

This review will focus on medication strategies for augmenting SRI treatment response in OCD treatment, including neuroleptic and serotonergic agents.

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder

Antipsychotic augmentation in SRI-refractory OCD is indicated in patients who have been treated for at least 3 months of maximal-tolerated therapy of an SRI, and evidence regarding the efficacy of quetiapine and olanzapine is inconclusive.

[Treatment of obsessive-compulsive disorder].

Treatment of obsessive compulsive disorder has not changed a lot since 2000 and for several infrequent patients with a "malignant syndrome", functional neuro-surgery using deep brain stimulation might be a safe and hopeful therapeutic technique.

Quetiapine augmentation in patients with treatment resistant obsessive–compulsive disorder: a single-blind, placebo-controlled study

The addition of quetiapine to ongoing SRI therapy has been found to be effective and well-tolerated approach in patients with refractory OCD.

Efficacy of Drug Treatment in Obsessive–Compulsive Disorder: a Meta-Analytic Review

Antidepressant drugs are effective in the short-term treatment of patients suffering from OCD; although the increase in improvement rate over placebo was greater for clomipramine than for SSRIs, direct comparison between these drugs showed that they had similar therapeutic efficacy on obsessive–compulsive symptoms.

Brain Stimulation Techniques in the Treatment of Obsessive-Compulsive Disorder: Current and Future Directions

Besides pharmacologic, behavioral, and neurosurgical approaches, different brain stimulation methods—transcranial magnetic stimulation, deep brain stimulation, and electroconvulsive therapy—have been investigated in treatment-resistant patients with OCD, with promising findings regarding efficacy, tolerability, and non-invasiveness and/or reversibility.

The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.

Although from a small, open-label study, these results suggest that aripiprazole holds promise for treating OCD, and larger, controlled studies of aripIPrazole as monotherapy and as augmentation in partial responders to selective serotonin reuptake inhibitors are needed.

Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial

Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.

The SNRIs may represent a valid alternative to the SSRIs, particularly in specific cases, and might be preferred for patients with certain types of treatment-resistant OCD or those with particular comorbid conditions.